However, patients with GAD antibodies often also have cerebellar ataxia and, less frequently, temporal lobe epilepsy (Balint and Bhatia, 2016; Martinez-Hernandez et al., 2016). This evidence concerns the gene GAD1 and aceruloplasminemia.